ASND
HOLD / NEUTRALMeanRevComposite
59.20
Technical
63.10
Fundamental
57.90
Rank
—
Price
259.62
Hurst
-0.11
As of
Aug 20, 2026
Daily
Ascendis Pharma A/S
HealthcareBiotechnologyAscendis Pharma is a biopharmaceutical firm headquartered in Denmark that develops treatments using its TransCon technology platform for rare endocrine and oncology conditions across global markets. The company currently markets SKYTROFA, a therapy for children with growth hormone deficiency, and YORVIPATH, a daily injection for adults with chronic hypoparathyroidism, while advancing additional endocrinology candidates and oncology programs through clinical trials.
Market cap
$16.5B
P/E (trailing)
19.25
P/E (forward)
25.14
PEG ratio
—
Dividend yield
0.00%
Beta
—
52w range
188.07 – 282.15
Return on equity
+118.78%
Profit margin
+70.84%
Revenue growth
+114.70%
Earnings growth
—
Price history
1Y: 251.27 (+24.6%) · range 196.01–277.18
Cycle position
54/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 29 · NOT READY · exit proximity 0
Conviction
28/ 100 · maturity 0%
Buildup.333
EMA entry setup.4229
Fundamentals.2558
Volume profile
POC
228.09
Price vs POC
+10.2%
Overhead supply
35%
Runway
open sky
Value area 221.04–258.65 · 35% of 120d volume overhead · moderate overhead
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -7.10% | +6.40% | mature |
| 40d | -11.60% | +6.40% | mature |